Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has been given a consensus rating of “Moderate Buy” by the six analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $14.00.

A number of equities research analysts recently commented on KLRS shares. Chardan Capital initiated coverage on Kalaris Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price objective for the company. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. Citizens Jmp started coverage on shares of Kalaris Therapeutics in a research note on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen lowered shares of Kalaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 31st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP acquired a new stake in shares of Kalaris Therapeutics during the third quarter worth about $1,394,000. WHI TRUST Co LLC bought a new stake in Kalaris Therapeutics during the 4th quarter worth approximately $823,000. Belpointe Asset Management LLC acquired a new stake in Kalaris Therapeutics during the 3rd quarter worth approximately $231,000. Fortis Capital Advisors LLC bought a new position in Kalaris Therapeutics in the third quarter valued at approximately $231,000. Finally, XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics in the second quarter valued at approximately $65,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Kalaris Therapeutics Stock Performance

KLRS opened at $10.02 on Wednesday. The company has a fifty day moving average price of $8.82 and a two-hundred day moving average price of $6.05. The firm has a market capitalization of $187.37 million, a PE ratio of -2.66 and a beta of -0.09. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.02.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.